Physitrack delivered a solid Q2, highlighted by margin expansion, positive free cash flow, and greater operational efficiency. Effects of the restructuring are now evident, with the company intensifying its focus on scalable, SaaS-led growth in the Wellness segment while keeping a tight grip on costs. Lifecare, which accounts for 78% of revenues, continued its steady performance, while growth in the smaller Wellness division (22% of revenues) remained muted, consistent with recent quarters. Outlook remains positive, and management sees room for further margin expansion ahead.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/